Could the clinical trial of the future begin before the patient takes the drug?
Research

Could the clinical trial of the future begin before the patient takes the drug?

By Marcus Reid · · 4 min read

His team started collecting blood and skin

Future Medical Research: The Possibility of Initiating Therapeutic Evaluations Before the Patient's Medicinal Product is Administered

In the advanced context of biomedical research, a revolutionary approach suggests that the clinical evaluation process could begin before any patient receives the treatment in question. This view, proposed following significant barriers to research into complex diseases such as multiple sclerosis, has evolved from the need to overcome the limitations of traditional preclinical models.

This exceptional progress comes from the work of Dr. Charles Howe, a neuroimmunologist at the Mayo Clinic, who about a decade ago reached a frustrating tipping point in studying how the immune system causes neuronal damage. Some previous studies relied exclusively on classical laboratory systems, which, while useful for clarifying some fundamental issues, failed to fully comprehend the biological complexity specific to the human organism that he wanted to understand. I 'm going to tell you something . Howe acknowledged that these preclinical models reached a ceiling, being unable to properly capture the necessary biological dynamics. This finding has triggered an intensive search for higher modelling methodologies for human diseases.

His team started collecting blood and skin samples from patients. These cells were later used to grow three-dimensional neuronal organoids; these structures represent microscopic replicas of human tissue, which Dr. Howe often calls them „brains in the dishes”. A major advantage of these models is their ability to preserve the essential biological traits of an individual, providing researchers with a platform to test hypotheses that would be impossible or ethically prohibited to explore directly on humans.

As this research progressed, Dr. Howe has expanded beyond simple analysis in individual laboratories to an innovative way of evaluating therapy, performed before the drug reaches the patient. Its concept, called the ex vivo clinical trial, involves outsourcing a part of the testing process from inside the patient's body. This system combines living biological models based on human cells - which he calls „biological avatars”- with computational simulations, i.e. „digital twins”. The results obtained in the laboratory are used to refine the digital model, and its predictions guide the next steps of research. This cycle takes place through a continuous feedback loop, with each test round adding new and valuable information. The ultimate aim is to obtain extensive knowledge of the mechanism of action of a treatment and to assess potential risks prior to clinical administration.

Interaction between biological avatars and digital twins

In parallel, researchers use engineering devices known

The term „biological avatarmay sound advanced, but its composing elements already exist in practice. Brooke Druliner, director of the Human Model Systems Core at the Mayo Clinic, points out: ”The power of these models lies in their ability to preserve vital aspects of the biology of each individual patient . Although not replicating the entire patient, the increased complexity of these systems allows for the capture of a greater proportion of relevant biology in human pathologies.

In parallel, researchers use engineering devices known as organ-on-a-chip or micro-physiological systems. These systems can replicate complex biological physiological conditions, such as blood flow, mechanical forces, and interactions between different cell types. These models provide access to viable human biology, which can be studied and manipulated multiple times.

The digital twin makes a distinct contribution; it is a software-based model that represents aspects of the patient's biology and physiology, using molecular data, clinical information and other types of data. These simulations allow an estimate of how a patient might respond to a specific intervention or treatment.

Researchers at the Mayo Clinic have already applied this method to critical care. In a specific investigation, they constructed models of digital twins for sepsis patients and proactively compared the responses predicted by the models to what actually happened during the first 24 hours of intensive care.

Howe explains that the synergy between the two components is essential. Researchers can expose the biological avatar to a drug and can quantify the response of cells or tissues, detecting both efficacy and signs of toxicity. These experimental results are then integrated into the digital twin, along with additional patient data. Gemini can simulate effects at different doses or therapeutic schemes, thus guiding future research decisions.

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.